LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Economic and outcomes consequences of TachoSil®: a systematic review.

Colombo, Giorgio L / Bettoni, Daria / Di Matteo, Sergio / Grumi, Camilla / Molon, Cinzia / Spinelli, Daniela / Mauro, Gaetano / Tarozzo, Alessia / Bruno, Giacomo M

Vascular health and risk management

2014  Volume 10, Page(s) 569–575

Abstract: Background: TachoSil(®) is a medicated sponge coated with human fibrinogen and human thrombin. It is indicated as a support treatment in adult surgery to improve hemostasis, promote tissue sealing, and support sutures when standard surgical techniques ... ...

Abstract Background: TachoSil(®) is a medicated sponge coated with human fibrinogen and human thrombin. It is indicated as a support treatment in adult surgery to improve hemostasis, promote tissue sealing, and support sutures when standard surgical techniques are insufficient. This review systematically analyses the international scientific literature relating to the use of TachoSil in hemostasis and as a surgical sealant, from the point of view of its economic impact.
Methods: We carried out a systematic review of the PubMed literature up to November 2013. Based on the selection criteria, papers were grouped according to the following outcomes: reduction of time to hemostasis; decrease in length of hospital stay; and decrease in postoperative complications.
Results: Twenty-four scientific papers were screened, 13 (54%) of which were randomized controlled trials and included a total of 2,116 patients, 1,055 of whom were treated with TachoSil. In the clinical studies carried out in patients undergoing hepatic, cardiac, or renal surgery, the time to hemostasis obtained with TachoSil was lower (1-4 minutes) than the time measured with other techniques and hemostatic drugs, with statistically significant differences. Moreover, in 13 of 15 studies, TachoSil showed a statistically significant reduction in postoperative complications in comparison with the standard surgical procedure. The range of the observed decrease in the length of hospital stay for TachoSil patients was 2.01-3.58 days versus standard techniques, with a statistically significant difference in favor of TachoSil in eight of 15 studies.
Conclusion: This analysis shows that TachoSil has a role as a supportive treatment in surgery to improve hemostasis and promote tissue sealing when standard techniques are insufficient, with a consequent decrease in postoperative complications and hospital costs.
MeSH term(s) Blood Loss, Surgical/prevention & control ; Cost-Benefit Analysis ; Drug Combinations ; Drug Costs ; Fibrinogen/adverse effects ; Fibrinogen/economics ; Fibrinogen/therapeutic use ; Hemostatic Techniques/adverse effects ; Hemostatic Techniques/economics ; Hemostatics/economics ; Hemostatics/therapeutic use ; Hospital Costs ; Humans ; Length of Stay/economics ; Outcome and Process Assessment, Health Care/economics ; Postoperative Hemorrhage/economics ; Postoperative Hemorrhage/prevention & control ; Thrombin/adverse effects ; Thrombin/economics ; Thrombin/therapeutic use ; Time Factors ; Treatment Outcome
Chemical Substances Drug Combinations ; Hemostatics ; TachoSil ; Fibrinogen (9001-32-5) ; Thrombin (EC 3.4.21.5)
Language English
Publishing date 2014-09-10
Publishing country New Zealand
Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID 2186568-1
ISSN 1178-2048 ; 1176-6344
ISSN (online) 1178-2048
ISSN 1176-6344
DOI 10.2147/VHRM.S63199
Shelf mark
Zs.A 6066: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top